APA (7th ed.) Citation

G, P. A. C., M, S., P, C., M, R., B, P., & JP, D. A. (2026). An opioid-withholding human laboratory paradigm during opioid agonist treatment for opioid use disorder and chronic pain: Phase- and dose-dependent effects of cannabidiol. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. https://doi.org/10.1038/s41386-026-02443-w

Chicago Style (17th ed.) Citation

G, P A Costa, Sofuoglu M, Compton P, Ranganathan M, Pittman B, and De Aquino JP. "An Opioid-withholding Human Laboratory Paradigm During Opioid Agonist Treatment for Opioid Use Disorder and Chronic Pain: Phase- and Dose-dependent Effects of Cannabidiol." Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology 2026. https://doi.org/10.1038/s41386-026-02443-w.

MLA (9th ed.) Citation

G, P A Costa, et al. "An Opioid-withholding Human Laboratory Paradigm During Opioid Agonist Treatment for Opioid Use Disorder and Chronic Pain: Phase- and Dose-dependent Effects of Cannabidiol." Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, 2026, https://doi.org/10.1038/s41386-026-02443-w.